X4’s Mavorixafor Liver Study Completion: What Investors Should Watch Next
TipRanks (Wed, 15-Jul 12:30 PM ET)
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 7-Jul 4:30 PM ET)
Globe Newswire (Wed, 1-Jul 7:00 AM ET)
X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
Globe Newswire (Wed, 27-May 7:00 AM ET)
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Wed, 6-May 7:15 AM ET)
Globe Newswire (Wed, 29-Apr 7:00 AM ET)
Market Chameleon (Fri, 24-Oct 6:30 AM ET)
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
X4 Pharmaceuticals trades on the NASDAQ stock market under the symbol XFOR.
As of July 15, 2026, XFOR stock price declined to $3.88 with 436,344 million shares trading.
XFOR has a beta of 1.98, meaning it tends to be more sensitive to market movements. XFOR has a correlation of 0.06 to the broad based SPY ETF.
XFOR has a market cap of $365.96 million. This is considered a Small Cap stock.
Last quarter X4 Pharmaceuticals reported $3 million in Revenue and -$.16 earnings per share. This fell short of revenue expectation by $-662,000 and exceeded earnings estimates by $.04.
In the last 3 years, XFOR traded as high as $58.50 and as low as $1.35.
The top ETF exchange traded funds that XFOR belongs to (by Net Assets): VTI, IWM, VXF, IWN, IWC.
XFOR has outperformed the market in the last year with a return of +162.2%, while the SPY ETF gained +21.8%. However, in the most recent history, XFOR shares have underperformed the stock market with its stock returning -7.6% in the last 3 month period and -16.9% for the last 2 week period, while SPY has returned +8.8% and +0.9%, respectively.
XFOR support price is $3.81 and resistance is $4.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XFOR shares will trade within this expected range on the day.